Oxidative Medicine and Cellular Longevity / 2019 / Article / Fig 6

Research Article

Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway

Figure 6

Myr treatment prevented Traf6 ubiquitination in vitro. (a) Myr (20 μM, preincubation with NRCM for 1 h) treatment prevented PE (50 μM, 30 min) induced TRAF6 ubiquitination and the phosphorylation of p38 and JNK1/2; (b) Myr treatment inhibited K63-Ub-induced TRAF6 ubiquitination in HEK293 cell; (c) Myr inhibited the interaction between Traf6 and TAK1, and TAK1phosphorylation. All experiments were repeated three times independently.
(a)
(b)
(c)